Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/80662
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival? |
Author: | Broadbridge, V. Karapetis, C. Beeke, C. Woodman, R. Padbury, R. Maddern, G. Kim, W. Roder, D. Hakendorf, P. Price, T. |
Citation: | British Journal of Cancer, 2013; 109(5):1338-1343 |
Publisher: | Nature Publishing Group |
Issue Date: | 2013 |
ISSN: | 0007-0920 1532-1827 |
Statement of Responsibility: | V T Broadbridge, C S Karapetis, C Beeke, R J Woodman, R Padbury, G Maddern, S W Kim, D Roder, P Hakendorf and T J Price |
Abstract: | <h4>Background</h4>Patients who relapse after potentially curative surgery for colorectal cancer tend to relapse within 5 years. There is, however, a group of patients who relapse beyond 5 years after resection and this late relapsing group may have a different behaviour and prognosis.<h4>Methods</h4>We analysed data from a prospective population-based registry to compare the characteristics and survival of relapsed patients with metachronous mCRC. Patients were categorised into relapse at <2, 2-5 and >5 years following their initial surgery. Univariate log-rank tests and multivariate Cox regression was performed to determine whether time to relapse (TTR) and other factors were associated with overall survival (OS).<h4>Results</h4>A total of 750 metachronous mCRC patients were identified. In all, 56% relapsed ≤2 years, 32.4% at 2-5 years and 11.6% >5 years. Median survival time from the time of diagnosis of mCRC for the three groups was 17.6, 26.1 and 27.5 months, respectively. Short TTR (<2 years) was significantly associated with survival (HR=0.75, 95% confidence interval (CI)=0.60-0.93 and HR=0.73, 95% CI=0.53-1.01, respectively, for 2-5 and >5 years vs <2 years, P<0.05). However, there was no significant difference in survival between patients who relapsed at 5 years or later compared with those who relapsed between 2 and 5 years (HR=0.98, 95% CI=0.69-1.38, P=0.90).<h4>Conclusion</h4>TTR within 2 years is an independent predictor of shorter survival time for mCRC patients who experience a relapse. These data do not support the hypothesis that patients who have late relapse late (>5 years) have a 'better' biology or survival compared with patients with a TTR of 2-5 years. |
Keywords: | colorectal cancer recurrence survival prognosis |
Rights: | Copyright 2013 Cancer Research UK. All rights reserved |
DOI: | 10.1038/bjc.2013.388 |
Published version: | http://dx.doi.org/10.1038/bjc.2013.388 |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.